289 patents
Page 9 of 15
Utility
Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
4 May 21
Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders.
Matthew William Burnell Trotter, Patrick Hagner, Courtney G. Havens, Rajesh Chopra, Anita Gandhi, Anke Klippel, Maria Yinglin Wang, Mike Breider, Suzana Sturlini Couto, Yan Ren, Paul Hollenbach, Kyle Macbeth
Filed: 5 Apr 18
Utility
Treatment of Immune-related and Inflammatory Diseases
29 Apr 21
Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases.
Peter H. Schafer, Ying Ye, Donna J. Sutherland, Rajesh Chopra, Anita Gandhi
Filed: 2 Sep 20
Utility
Methods for Treating a Hematological Cancer and the Use of Companion Biomarkers for 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
22 Apr 21
A method of identifying a subject having a hematological cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the hematological cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
Maria Soraya Carrancio ANTON, Celia Fontanillo FONTANILLO, Shailaja KASIBHATLA, Antonia LOPEZ-GIRONA, Gang LU, Kai WANG
Filed: 20 Oct 20
Utility
Methods of Treating Chronic Lymphocytic Leukemia Using 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
22 Apr 21
Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with obinutuzumab, for treating, preventing or managing chronic lymphocytic leukemia/small lymphocytic lymphoma.
Preethi Janardhanan, Shailaja Kasibhatla, Antonia Lopez-Girona, Michael Pourdehnad
Filed: 20 Oct 20
Utility
Pharmaceutical Compositions Comprising (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE and Methods of Using the Same
22 Apr 21
Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent.
Sreenivas S. Bhat, Fabien Boulineau, Donna Carroll, Tracy Lee Gaebele, Yuchuan Gong, Isabel Minjung Hong, Zhengmao Li, Ye Tian
Filed: 20 Oct 20
Utility
Substituted 4-AMINOISOINDOLINE-1,3-DIONE Compounds and Second Active Agents for Combined Use
22 Apr 21
Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies.
Maria Soraya Carrancio Anton, Tonia J. Buchholz, Henry Chang, Ellen Filvaroff, Shailaja Kasibhatla, Antonia Lopez-Girona, Adithi Mohan, Rama Krishna Narla, Michael Pourdehnad
Filed: 20 Oct 20
Utility
Methods of Treating Hematological Malignancies Using 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
22 Apr 21
Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing hematological malignancies.
Maria Soraya Carrancio Anton, Tonia J. Buchholz, Shailaja Kasibhatla, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
Filed: 20 Oct 20
Utility
Solid Forms Comprising (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE and Salts Thereof, and Compositions Comprising and Methods of Using the Same
22 Apr 21
Provided herein are formulations, processes, solid forms and methods of use relating to salts of and solid forms comprising free base or salts of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione.
Lianfeng Huang, Wenju Wu
Filed: 20 Oct 20
Utility
Combination therapy for treatment of hematological cancers and solid tumors
13 Apr 21
Provided herein are methods for treating, preventing, and/or managing hematological cancers and solid tumors using combination therapy of 3-(5-amino-2-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione and checkpoint inhibitors.
Anita Gandhi, Hsiling Chiu, Michael Pourdehnad
Filed: 1 Jul 16
Utility
Solid Forms Comprising 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE and a Coformer, Compositions and Methods of Use Thereof
8 Apr 21
Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer.
G. Patrick Stahly, David Jonaitis, Ho-Wah Hui, Kevin J. Klopfer
Filed: 1 Oct 20
Utility
Methods for Treating Diffuse Large B-cell Lymphoma and the Use of Biomarkers As a Predictor to Responsiveness to Drugs
8 Apr 21
In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs.
Matthew William Burnell Trotter, Alberto Risueno Perez, Michael Pourdehnad, Anita Gandhi, Patrick Hagner
Filed: 18 May 20
Utility
Combination Therapy for Treating Malignancies
8 Apr 21
Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
Vivek Saroj Kumar Chopra, Jorge DiMartino, Laurie A. Kenvin, Robert Douglas Knight, Kyle MacBerth, Krishnan Viswanadhan, Qiang Xu, Samuel V. Agresta
Filed: 21 May 20
Utility
Methods for Measuring Small Molecule Affinity to Cereblon
8 Apr 21
A complex comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN, and uses thereof for identifying therapeutic compounds.
Philip Paul CHAMBERLAIN, Mary MATYSKIELA, Godrej KHAMBATTA
Filed: 18 Sep 20
Utility
Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis
6 Apr 21
Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized.
Stewart Abbot, Tianjian Li, Bitao Liang
Filed: 14 Feb 19
Utility
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
6 Apr 21
A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
Joshua Hansen, Courtney G. Havens, Antonia Lopez-Girona, Gang Lu, Lilly L. Wong
Filed: 22 May 19
Utility
Formulations of 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE
25 Mar 21
Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein.
Anthony J. Tutino, Michael T. Kelly
Filed: 8 Dec 20
Utility
Combination Therapy Using Adoptive Cell Therapy and Checkpoint Inhibitor
11 Mar 21
Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and the use of a checkpoint inhibitor, such as an anti-PD-L1 antibody or antigen-binding fragment thereof for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture.
Stanley R. FRANKEL, Jens HASSKARL, Oliver MANZKE
Filed: 31 Jan 19
Utility
Methods of Treating Immune Disorders Using PD-1 Binding Proteins
11 Mar 21
Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
Henry H. Chan, Eun Mi Hur, Roli Khattri, Monica Leung, Garth E. Ringheim, Peter H. Schafer
Filed: 31 Jul 20
Utility
Isotopologues of 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE
11 Mar 21
Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium.
Joshua Hansen, Weihong Zhang
Filed: 31 Dec 18
Utility
ANTI-CD47 Antibodies and Uses Thereof
25 Feb 21
Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47.
Aaron Sato, Ryan Stafford, Junhao Yang
Filed: 29 Oct 20